Gujarat Inject (Kerala) Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Gujarat Inject (Kerala) Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Shareholder Slice Ratio: Share count rose 199% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than almost all Healthcare companies in India.
- Profit Cash Ratio: Over the last 3 years, every ₹100 of reported profit came with ₹400 of operating cash. Higher than 96% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹400Over the last 3 years, every ₹100 of reported profit came with ₹400 of operating cash.
Higher than 96% of Healthcare companies in India.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 83% of Healthcare companies in India.
Growth Efficiency Ratio
₹5Sales grew 20,802% in 3 years; of every extra ₹100 of sales, ₹5 became extra profit.
Lower than 80% of Healthcare companies in India.
Asset Productivity Ratio
+20802% / +11993%In 3 years sales changed by +20802% while total assets changed by +11993%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
No debt dueNo debt falls due within a year, according to the latest yearly balance sheet.
Cash Cushion Ratio
+0%Cash, after subtracting all debt, equals 0% of its market value (net cash).
Higher than 61% of Healthcare companies in India.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Gujarat Inject (Kerala) Limited owes ₹0.68 for every ₹1 it owns. Net profit rose 78% in the year to Mar 2026, and grew 254% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
46.9Investors pay ₹46.9 for every ₹1 of Gujarat Inject (Kerala) Limited's yearly profit, higher than 67% of Healthcare companies in India.
P/B ratio
12.20The share price is 12.20 times Gujarat Inject (Kerala) Limited's book value per share, higher than 87% of Healthcare companies in India.
Market cap
₹144 CrThe total market value of all of Gujarat Inject (Kerala) Limited's shares at today's price (share price × number of shares), smaller than 94% of Healthcare companies in India. PosiCap size class: Micro Cap.
Net worth (book value)
₹12 CrWhat Gujarat Inject (Kerala) Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹0.81Net worth divided by the number of shares. The share price of ₹9.85 is 12.2 times this, which is the P/B above.
Return on equity (ROE)
25.9%Gujarat Inject (Kerala) Limited earned 25.9% on its shareholders' money over the last year, higher than 89% of Healthcare companies in India.
Owes vs Owns
0.68×Gujarat Inject (Kerala) Limited owes ₹0.68 for every ₹1 it owns (moderate), higher than 96% of Healthcare companies in India.
Dividend yield
NoneGujarat Inject (Kerala) Limited does not currently pay a dividend.
Revenue growth
+91%Revenue rose 91% in the year to Mar 2026, and grew 493% a year on average over 3 years.
Profit growth
+78%Net profit rose 78% in the year to Mar 2026, and grew 254% a year on average over 3 years.
Profit margin
5.0%Gujarat Inject (Kerala) Limited keeps ₹5 of every ₹100 of revenue as net profit.
Cash quality
11.7×Cash from Gujarat Inject (Kerala) Limited's business was 11.7× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
11539.5×Gujarat Inject (Kerala) Limited's operating profit covered its interest costs 11539.5 times in the year to Mar 2026.
Cash vs debt
Net cashGujarat Inject (Kerala) Limited held ₹1 Cr more cash than debt (net cash) at Mar 2026.
Questions
What is Gujarat Inject (Kerala) Limited's P/E ratio?
Investors pay ₹46.9 for every ₹1 of Gujarat Inject (Kerala) Limited's yearly profit, higher than 67% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Gujarat Inject (Kerala) Limited: ₹144 Cr ÷ ₹12 Cr (31 Mar 2026) = 12.2.
What is Gujarat Inject (Kerala) Limited's return on equity?
Gujarat Inject (Kerala) Limited earned 25.9% on its shareholders' money over the last year, higher than 89% of Healthcare companies in India.
How much does Gujarat Inject (Kerala) Limited owe compared with what it owns?
Gujarat Inject (Kerala) Limited owes ₹0.68 for every ₹1 it owns (moderate), higher than 96% of Healthcare companies in India.
Does Gujarat Inject (Kerala) Limited pay a dividend?
No. Gujarat Inject (Kerala) Limited does not currently pay a dividend.
Is Gujarat Inject (Kerala) Limited's revenue growing?
Revenue rose 91% in the year to Mar 2026, and grew 493% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.